- Home
- PHGE vs YHC Comparison
PHGE vs YHC Comparison
Compare PHGE & YHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- YHC
- Stock Information
- Founded
- PHGE 2015
- YHC 2021
- Country
- PHGE Israel
- YHC United States
- Employees
- PHGE N/A
- YHC N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- YHC Beverages (Production/Distribution)
- Sector
- PHGE Health Care
- YHC Consumer Staples
- Exchange
- PHGE Nasdaq
- YHC Nasdaq
- Market Cap
- PHGE 13.3M
- YHC N/A
- IPO Year
- PHGE N/A
- YHC N/A
- Fundamental
- Price
- PHGE $0.56
- YHC $1.88
- Analyst Decision
- PHGE Strong Buy
- YHC Strong Buy
- Analyst Count
- PHGE 2
- YHC 2
- Target Price
- PHGE $23.00
- YHC $175.00
- AVG Volume (30 Days)
- PHGE 51.4K
- YHC 113.9K
- Earning Date
- PHGE 05-15-2025
- YHC 05-20-2025
- Dividend Yield
- PHGE N/A
- YHC N/A
- EPS Growth
- PHGE N/A
- YHC N/A
- EPS
- PHGE N/A
- YHC N/A
- Revenue
- PHGE N/A
- YHC $2,501,660.00
- Revenue This Year
- PHGE N/A
- YHC $69.97
- Revenue Next Year
- PHGE N/A
- YHC $403.29
- P/E Ratio
- PHGE N/A
- YHC N/A
- Revenue Growth
- PHGE N/A
- YHC 123.24
- 52 Week Low
- PHGE $0.48
- YHC $2.32
- 52 Week High
- PHGE $4.99
- YHC $98.00
- Technical
- Relative Strength Index (RSI)
- PHGE 44.80
- YHC N/A
- Support Level
- PHGE $0.54
- YHC N/A
- Resistance Level
- PHGE $0.58
- YHC N/A
- Average True Range (ATR)
- PHGE 0.04
- YHC 0.00
- MACD
- PHGE 0.00
- YHC 0.00
- Stochastic Oscillator
- PHGE 32.83
- YHC 0.00
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.